Affordable Access

Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery.

Authors
  • Carrier, M1
  • Ménasché, P
  • Levy, J H
  • Newman, M F
  • Taylor, K M
  • Haverich, A
  • Chen, J C
  • Shernan, S K
  • Van de Werf, F
  • van der Laan, M
  • Todaro, T G
  • Adams, P X
  • Verrier, E D
Type
Published Article
Journal
The Journal of thoracic and cardiovascular surgery
Publication Date
February 2006
Volume
131
Issue
2
Pages
352–356
Identifiers
PMID: 16434264
Source
Medline
License
Unknown

Abstract

Inhibition of complement activation by pexelizumab resulted in a decreased mortality at 180 days among 218 patients who underwent combined aortic valve replacement and coronary artery bypass grafting surgery. Additional studies are warranted to confirm this decrease in mortality with pexelizumab in combined aortic valve replacement and coronary artery bypass grafting procedures.

Report this publication

Statistics

Seen <100 times